Royalty Pharma plc

NasdaqGS:RPRX Stock Report

Market Cap: US$29.8b

Royalty Pharma Future Growth

Future criteria checks 5/6

Royalty Pharma is forecast to grow earnings and revenue by 38.8% and 15.6% per annum respectively. EPS is expected to grow by 13.5% per annum. Return on equity is forecast to be 27.3% in 3 years.

Key information

38.8%

Earnings growth rate

13.48%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate15.6%
Future return on equity27.34%
Analyst coverage

Low

Last updated08 May 2026

Recent future growth updates

Recent updates

Narrative Update • May 02

RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook

Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
Narrative Update • Apr 17

RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside

Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.
Narrative Update • Apr 03

RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook

Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
Narrative Update • Mar 19

RPRX: Royalty Deals And Buybacks Will Support Future Upside

Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.
Narrative Update • Mar 05

RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential

Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.
Narrative Update • Feb 19

RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside

Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.
Seeking Alpha • Feb 12

Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View

Summary Royalty Pharma delivered robust 2025 results, with Q4 receipts up 17% to $856 million and full-year portfolio receipts at $3.25 billion. The company deployed $2.6 billion into 9 new royalties and repurchased $1.2 billion in shares, reflecting disciplined capital allocation and shareholder focus. Even factoring in patent expiries and a more conservative growth outlook, valuation remains attractive, supported by sector momentum and sustained capital returns. Read the full article on Seeking Alpha
Analysis Article • Feb 11

Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235

Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...
Narrative Update • Feb 05

RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns

Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.
Analysis Article • Jan 22

Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's

Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...
Narrative Update • Jan 21

RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside

Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.
Narrative Update • Jan 07

RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power

Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.
Narrative Update • Dec 15

RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price

Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.
Narrative Update • Dec 01

RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion

Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.
Narrative Update • Nov 17

RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade

Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.
Narrative Update • Nov 02

RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside

Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.
Narrative Update • Sep 04

Emerging Therapies And Licensing Will Expand Royalty Opportunities

Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.
Analysis Article • Jul 06

Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...
Analysis Article • May 31

Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Seeking Alpha • Feb 13

Royalty Pharma: Delivering Growth With A Positive Story Ahead

Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking Alpha
Seeking Alpha • Jan 15

Royalty Pharma: Key Strategic Updates To Be Priced In

Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking Alpha
Seeking Alpha • Nov 09

Royalty Pharma: Massive Opportunity Ahead

Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqGS:RPRX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283,9532,7123,5843,3483
12/31/20273,6592,1993,3223,0075
12/31/20263,4301,5973,1952,8535
3/31/20262,4418264632,612N/A
12/31/20252,3787717922,490N/A
9/30/20252,3507669452,405N/A
6/30/20252,3051,0227132,406N/A
3/31/20252,2641,0942802,700N/A
12/31/20242,2648592632,769N/A
9/30/20242,2661,145-2122,799N/A
6/30/20242,2386734012,669N/A
3/31/20242,2397991,0192,619N/A
12/31/20232,3551,1358722,988N/A
9/30/20232,3241841,4222,785N/A
6/30/20232,3612555222,750N/A
3/31/20232,3593323742,718N/A
12/31/20222,237434022,144N/A
9/30/20222,2475074012,064N/A
6/30/20222,2594663121,995N/A
3/31/20222,2786022631,952N/A
12/31/20212,289620-1742,018N/A
9/30/20212,286783-7322,093N/A
6/30/20212,239972-1592,132N/A
3/31/20212,195493-4962,090N/A
12/31/20202,122495-1482,035N/A
9/30/20202,0081,7451041,947N/A
6/30/20201,9341,8637931,858N/A
3/31/20201,8802,0521,0931,705N/A
12/31/20191,8142,349N/A1,667N/A
12/31/20181,7951,378N/A1,618N/A
12/31/20171,5981,210N/A1,418N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RPRX's forecast earnings growth (38.8% per year) is above the savings rate (3.5%).

Earnings vs Market: RPRX's earnings (38.8% per year) are forecast to grow faster than the US market (16.8% per year).

High Growth Earnings: RPRX's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: RPRX's revenue (15.6% per year) is forecast to grow faster than the US market (11.6% per year).

High Growth Revenue: RPRX's revenue (15.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RPRX's Return on Equity is forecast to be high in 3 years time (27.3%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/13 20:04
End of Day Share Price 2026/05/13 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Royalty Pharma plc is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Geoffrey MeachamCitigroup Inc
Prem ChulakiCrispIdea